Company intelligence / Profile preview
GigaGen Inc.
San Carlos, California, United Statesgigagen.com ↗
- Ownership
- Public · GRFS
- Employees
- ~42
- Development stage
- Phase 1
01
Overview
GigaGen has developed recombinant hyperimmune drugs including GIGA-2050 for COVID-19, with plans to submit an IND. Their lead oncology asset, GIGA-564, is an anti-CTLA-4 monoclonal antibody that has demonstrated improved anti-tumor efficacy in vivo.[3][5]
- Therapeutic areas
- OncologyImmunologyInfectious Diseases
- Modalities
- Recombinant polyclonal antibodiesmonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
Grifols
Beyond the preview
Go deeper on GigaGen Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GigaGen Inc..